Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

Young patients with advanced Hodgkin's lymphoma, a cancer of the lymphatic system, now have a better chance of having their ...

A clinical trial has shown that a new chemotherapy for Hodgkin’s lymphoma has fewer harmful effects on patients’ later fertility than the previous treatment / Publication in “The Lancet Oncology” ...

Abdera Therapeutics Inc., a clinical-stage biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and develop tunable precision radiopharmaceuticals for ...

Hernán’s appointment comes at a pivotal moment as Takeda intensifies its focus on advancing sustainable, value-based ...

Discover why Takeda Pharmaceutical Company Limited remains a solid Buy. Click to explore TAK and its drug pipeline, growth ...

Takeda offers strong cash flow, solid growth in key areas, and a 4.4% yield, but trades at a premium despite its fundamentals ...

Takeda is on track to submit its much-hyped narcolepsy drug to regulators this fiscal year after the orexin receptor 2 (OX2R) ...

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the 13 Best Japanese Stocks to Buy According to Hedge Funds. On ...

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

An FDA advisory committee ruled in two separate votes that two belantamab mafodotin combination regimens should not be used ...